Maddie Meyer/Getty Images News Moderna ( NASDAQ: MRNA ) shares dropped on Wednesday after the latest efficacy data for its newly approved vaccine for respiratory syncytial virus (RSV) disappointed Wall Street. Last month, the U.S.
FDA approved the messenger RNA-based vaccine branded as mRESVIA to protect adults aged 60 years and older from lower respiratory tract disease (LRTD) caused by RSV infection. Ahead of a CDC’s vaccine advisory committee meeting this week, Moderna ( MRNA ) said Wednesday that mRESVIA’s vaccine efficacy against two or more LRTD symptoms stood at 50% as of March. The data was part of a company’s presentation before the CDC’s Advisory Committee on Immunization Practices (ACIP), whose opinion the regulator uses to decide on mRESVIA’s market rollout.
GSK ( GSK ) and Pfizer ( PFE ) currently dominate the market for RSV vaccines after the FDA approved their traditionally developed shots, Arexvy and Abrysvo, for older adults last year. In reaction to the latest data for Moderna’s ( MRNA ) shot, Jefferies analyst Michael Yee said the efficacy level was on the lower end of expectations. More on Moderna Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc.
(MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript) CDC 'preparing for the possibility' bird flu could spread more easily FDA recommends KP.2 strain be used in updated COVID-19 shots.
